Preclinical development of a molecular clamp‐stabilised subunit vaccine for severe acute respiratory syndrome coronavirus 2
Clinical & Translational Immunology2021Vol. 10(4), pp. e1269–e1269
Citations Over TimeTop 10% of 2021 papers
Daniel Watterson, Danushka K. Wijesundara, Naphak Modhiran, Francesca L. Mordant, Zheyi Li, Michael S. Avumegah, Christopher L. D. McMillan, Julia Lackenby, Kate Guilfoyle, Geert van Amerongen, Koert J. Stittelaar, Stacey T. M. Cheung, Summa Bibby, Mallory Daleris, Kym Hoger, Marianne Gillard, Eve Radunz, Martina L. Jones, Karen Hughes, Benjamin Hughes, Justin B. Goh, David Edwards, Judith A. Scoble, Lesley A. Pearce, Lukasz Kowalczyk, Tram Phan, Mylinh La, Louis Lu, Tam Pham, Qi Zhou, David A. Brockman, Sherry J. Morgan, Cora Lau, Mai H. Tran, Peter Tapley, Fernando Villalón‐Letelier, James Barnes, Andrew Young, Noushin Jaberolansar, Connor A. P. Scott, Ariel Isaacs, Alberto A. Amarilla, Alexander A. Khromykh, Judith MA van den Brand, Patrick C. Reading, Charani Ranasinghe, Kanta Subbarao, Trent P. Munro, Paul R. Young, Keith J. Chappell
Abstract
The SARS-CoV-2 Sclamp vaccine candidate is compatible with large-scale commercial manufacture, stable at 2-8°C. When formulated with MF59 adjuvant, it elicits neutralising antibodies and T-cell responses and provides protection in animal challenge models.
Related Papers
- An overview of scientific and regulatory issues for the immunogenicity of biological products.(2003)
- → Aggregation and Immunogenicity of Therapeutic Proteins(2010)38 cited
- → Immunogenicity of Therapeutic Proteins(2010)29 cited
- DDA is More Efficacious Than MPL as Adjuvants That Enhanced Immunogenicity and Protection of Combined DNA Vaccine Against Mycobacterium tuberculosisa(2005)
- → Immunogenicity(2015)